FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS

被引：0
|
作者：
Salvatore, Lisa
Loupakis, Fotios [2 ]
Cremolini, Chiara
Schirripa, Marta
Masi, Gianluca [1 ]
Antoniotti, Carlotta
Fornaro, Lorenzo [1 ]
Sensi, Elisa [3 ]
Lupi, Cristiana [3 ]
Bergamo, Francesca [4 ]
Lonardi, Sara [4 ]
Zagonel, Vittorina [4 ]
Fontanini, Gabriella [3 ]
Falcone, Alfredo
机构：
[1] Azienda Osped Univ Pisana, Ist Toscano Tumori, UO Oncol Med 2, Pisa, Italy
[2] Univ So Calif, Pisa, Italy
[3] Univ Pisa, Div Anat Patol, Dipartimento Chirurg, Pisa, Italy
[4] Ist Oncol Veneto IRCCS, Padua, Italy
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [11] Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
    Yosuke Kito
    Hironaga Satake
    Hiroya Taniguchi
    Takeshi Yamada
    Yoshiki Horie
    Taito Esaki
    Tadamichi Denda
    Hisateru Yasui
    Naoki Izawa
    Toshiki Masuishi
    Toshikazu Moriwaki
    Keita Mori
    Kentaro Yamazaki
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 277 - 284
  • [12] FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
    Damato, Angela
    Bergamo, Francesca
    Antonuzzo, Lorenzo
    Nasti, Guglielmo
    Iachetta, Francesco
    Romagnani, Alessandra
    Gervasi, Erika
    Larocca, Mario
    Pinto, Carmine
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [13] Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment
    Huang, Ching-Wen
    Yeh, Yung-Sung
    Ma, Cheng-Jen
    Tsai, Hsiang-Lin
    Chen, Chao-Wen
    Huang, Ming-Yii
    Lu, Chien-Yu
    Wu, Jeng-Yih
    Wang, Jaw Yuan
    CHEMOTHERAPY, 2017, 62 (01) : 80 - 84
  • [14] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
    Gaspar, E.
    Juarez Marroqui, A.
    Vicent, J.
    Llorca, C.
    Orts, D.
    Galan, A.
    Barrajon, E.
    Cervera Grau, J.
    Giner, V.
    Macia, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [15] FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer
    Cervantes, A.
    Prager, G. W.
    ESMO OPEN, 2023, 8 (02)
  • [16] FOLFOXIRI plus Bevacizumab in metastatic colorectal Cancer
    不详
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (07): : 630 - 630
  • [17] Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer
    Bai, Long
    Wang, Feng
    Li, Zhe-zhen
    Ren, Chao
    Zhang, Dong-sheng
    Zhao, Qi
    Lu, Yun-xin
    Wang, De-shen
    Ju, Huai-qiang
    Qiu, Miao-zhen
    Wang, Zhi-qiang
    Wang, Feng-hua
    Xu, Rui-hua
    MEDICINE, 2016, 95 (51) : e4531
  • [18] Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial
    Cremolini, Chiara
    Malmorino, Federica
    Bergamo, Francesca
    Aprile, Giuseppe
    Salvatore, Lisa
    Masi, Gianluca
    Dell'Aquila, Emanuela
    Antoniotti, Carlotta
    Murgioni, Sabina
    Allegrini, Giacomo
    Borelli, Beatrice
    Gemma, Donatello
    Casagrande, Mariaelena
    Granetto, Cristina
    Delfanti, Sara
    Di Donato, Samantha
    Schirripa, Marta
    Sensi, Elisa
    Tonini, Giuseppe
    Lonardi, Sara
    Fontanini, Gabriella
    Boni, Luca
    Falcone, Alfredo
    EUROPEAN JOURNAL OF CANCER, 2019, 109 : 175 - 182
  • [19] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ahmet, Bilici
    Uygun, Kazim
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
  • [20] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study
    Antonuzzo, Lorenzo
    Giommoni, Elisa
    Pastorelli, Davide
    Latiano, Tiziana
    Pavese, Ida
    Azzarello, Domenico
    Aieta, Michele
    Pastina, Ilaria
    Di Fabio, Francesca
    Bertolini, Alessandro
    Corsi, Domenico Cristiano
    Mogavero, Selene
    Angelini, Valentina
    Pazzagli, Mario
    Di Costanzo, Francesco
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (23) : 7281 - 7288
12345